Latest Breaking News On - Carrie bourdow - Page 7 : comparemela.com

Trevena Reports First Quarter 2021 Results May 06, 2021 07:00 ET | Source: Trevena Inc. Trevena Inc. Company reaffirms YE target of 100 formulary approvals for OLINVYK® Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and cognitive function TRV027 selected for two large, multi-site COVID-19 studies led by NIH / Vanderbilt University Medical Center and REMAP-CAP TRV045 IND filing remains on track for 1H 2021 with a lead target indication of diabetic neuropathic pain $97.7M cash at Q1 funds operations through YE 2022 th CHESTERBROOK, Pa., May 06, 2021 (GLOBE NEWSWIRE) Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the first quarter ended March 31, 2021, and provided an overview of its recent operational

Carrie bourdowVanderbilt university medical centerTrevena incChief executive officerRecent corporate highlightsNasdaq trvnTrevena incNew product launchDiabetic neuropathic painNeuropathic painCovid 19வாண்டர்பில்ட் பல்கலைக்கழகம் மருத்துவ மையம்திரேவென இன்க்தலைமை நிர்வாகி அதிகாரிசமீப பெருநிறுவன சிறப்பம்சங்கள்